In a slap in the face aimed right at one of the world’s largest drug­mak­ers, BeiGene $BGNE said to­day that it is be­ing forced by Chi­nese of­fi­cials to halt im­ports of the can­cer drug Abrax­ane.

Ac­cord­ing to the Chi­na-based BeiGene, the Chi­na Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion — or NM­PA — or­dered the halt fol­low­ing an in­spec­tion of one of Bris­tol My­ers’ US fa­cil­i­ties used to make the drug. That’s a rare event in the glob­al drug mak­ing world, where the FDA is known for its reg­u­lar ci­ta­tions for over­seas drug man­u­fac­tur­ers.

BeiGene did not ex­plain what the Chi­nese of­fi­cials found in the in­spec­tion that caused the prob­lems for Abrax­ane. But the com­pa­ny said it’s scram­bling to find an­oth­er sup­pli­er for the drug, which it li­censed from Cel­gene, as they try to re­solve the is­sues raised by Chi­nese in­spec­tors.

Ac­cord­ing to a Bris­tol My­ers spokesman:

A re­cent in­spec­tion of the Chi­nese gov­ern­men­tal body at a third-par­ty man­u­fac­tur­ing site that pro­duces Abrax­ane for the Chi­na mar­ket iden­ti­fied op­por­tu­ni­ties for im­prove­ment. We are work­ing close­ly with the Chi­nese health au­thor­i­ties and the man­u­fac­tur­ing site to im­ple­ment cor­rec­tive ac­tions and pre­ven­tive mea­sures to ad­dress their find­ings. In par­al­lel, we are pur­su­ing li­cen­sure of an al­ter­nate man­u­fac­tur­ing site as part of the path for­ward in Chi­na.

An­a­lysts were quick to seize on this as a pos­si­ble is­sue for in­vestors who own some of Bris­tol My­ers’ $9 CVRs from the Cel­gene buy­out. The CVR is based on a sched­ule of FDA ap­provals on 3 drugs over the next year.

Re­la­tions be­tween Chi­na and the US have been fraught with ten­sion ever since Don­ald Trump be­came pres­i­dent and be­gan to pres­sure Chi­na to make some fun­da­men­tal changes in the way they han­dle ex­ports to the US. Re­cent­ly, that pres­sure has watched up dur­ing the pan­dem­ic. But Chi­na, which was hit first by the out­break, has been the first to de­clare vic­to­ry over the coro­n­avirus.

The FDA today approved Emergent BioSolutions’ Narcan brand naloxone nasal spray for over-the-counter sales. The nod was expected and comes on the heels of a unanimous 19-0 advisory committee vote in favor of approval last month.

The move to OTC means the opioid overdose reversal agent will now be available on grocery, convenience and gas stations shelves, as well as potentially for purchase online.

The mRNA player Moderna is further cementing its presence on the African continent.

Moderna announced on Thursday that it has finalized an agreement with Kenya’s government to partner up and bring an mRNA manufacturing facility to the east African nation. The new facility aims to manufacture up to 500 million doses of vaccines annually. Moderna also said the new facility will have the ability to spike its production capabilities to respond to public health emergencies on the continent or globally.

When Vigil Neuroscience filed its IPO papers in late 2021, the biotech revealed that the FDA had just cleared its Phase I trial — but with a partial clinical hold that limited dosing to under a certain level.

More than a year later, the FDA has lifted the hold.

Vigil is now free to dose VGL101, an antibody targeting TREM2, at levels higher than 20 mg/kg in its ongoing and future clinical trials in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), an inherited condition that affects the brain and spinal cord.